Vertex- Scottish govt. sign cystic fibrosis treatment access contract
Category: #health  By Mateen Dalal  Date: 2019-09-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Vertex- Scottish govt. sign cystic fibrosis treatment access contract

As part of the 5-year agreement, Vertex will also be collecting real world data on these medicines.

Vertex Pharmaceuticals Incorporated has reportedly announced that Scotland based patients suffering from cystic fibrosis will now be eligible to have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor subsequently after signing an agreement for access.

Ludovic Fenaux, Senior VP, Vertex International, reportedly stated that the company would like to appreciate the Scottish authorities for their partnership and the flexible and collaborative way which helped both of the entities have worked together to figure out an access solution. It means that about 400 eligible patients suffering from cystic fibrosis in Scotland will now be able to have access to SYMKEVI or ORKAMBI, he further added.

Apparently, as part of the 5-year agreement, Vertex will also be collecting real world data on these medicines. This data will further support any future submissions to the Scottish Medicines Consortium (SMC).

Reportedly, Vertex cystic fibrosis medicines have been reimbursed in 17 countries around the world. These 17 countries include Australia, Austria, Denmark, Germany, Italy, the Republic of Ireland, the Netherlands, the U.S. and Sweden.

According to reliable sources, around 900 people in Scotland are suffering from CF. In the United Kingdom, 32 years is the median age of death of people suffering from CF. NHS Scotland has estimated that one in 24 Scots have a CFTR mutation. If this mutation is carried by both parents then it may lead to a baby being born with CF.

For the record, Vertex is a multinational biotechnology firm which invests in innovative initiatives to develop medicines for patients suffering from serious disorders. The company owns three approved medicines which can treat the primary cause of cystic fibrosis (CF).  Cystic fibrosis is a rare and life-threatening genetic disorder. There are several ongoing clinical and research programs going on to develop efficient treatment of CF.

Source Credit:

https://www.businesswire.com/news/home/20190912005349/en/Vertex-Announces-New-Access-Agreement-Scottish-Government

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Airbus cuts back production of jets amid rising COVID-19 concerns
Airbus cuts back production of jets amid rising COVID-19 concerns
By Mateen Dalal

Aircraft manufacturer Airbus is reportedly set to reduce jet plane production by a third. This decision has been taken considering the possibility of further impact on the global aviation industry by the coronavirus epidemic, even after the easing of...

AIVITA declares updates for AV-GMB-1 clinical trial in GBM patients
AIVITA declares updates for AV-GMB-1 clinical trial in GBM patients
By Mateen Dalal

AIVITA Biomedical, Inc., a biotech firm developing innovative cell therapies, has recently announced updates to the survival data after the year-end analysis of the ongoing AV-GBM-1 Phase 2 clinical trial in newly diagnosed glioblastoma (GBM) patient...

Lufthansa to shut down Germanwings & de-commission over 40 aircrafts
Lufthansa to shut down Germanwings & de-commission over 40 aircrafts
By Mateen Dalal

Lufthansa, the flag carrier and largest German airline, is reportedly shutting down its Germanwings, a low-cost airline, due to the rising impact of coronavirus on the business. The airline is also planning to de-commission over 40 aircrafts due to t...